Literature DB >> 20477526

Identification of a beta-casein-like peptide in breast nipple aspirate fluid that is associated with breast cancer.

Edward R Sauter1, Wade Davis, Wenyi Qin, Sarah Scanlon, Brian Mooney, Karen Bromert, William R Folk.   

Abstract

AIMS: Nipple aspirate fluid was collected prospectively from women scheduled for diagnostic breast surgery in order to determine protein masses associated with breast cancer, subsets of women with a unique proteomic profile and a breast cancer predictive model. MATERIALS &
METHODS: Breast nipple aspirate fluid was collected preoperatively in 163 breasts from 125 women and analyzed for changes in cell morphology and by SELDI-TOF mass spectrometry over approximately a 44 kDa range (1.5-45 kDa) using IMAC30, CM10 and Q10 ProteinChips.
RESULTS: Considering all samples, 16 protein masses were associated with the presence of cancer, the most discriminating being 3592, 6570/6580 and 15870 Da. Excluding women with pathologic nipple discharge or those with a papilloma identified an additional protein of 6383 Da. The best cancer detection models included Breast Imaging Reporting and Data System, age, and either the 4262 (best sensitivity: >87%) or 3592 (best specificity: >94%) peak. MALDI-TOF mass spectrometry demonstrated the 3592 peak, which was most discriminating in many of our cancer prediction models, to be a beta-casein-like peptide.
CONCLUSION: Differential nipple aspirate fluid proteomic expression exists between women with/without breast cancer. The most discriminating protein identified is a beta-casein-like peptide not previously described. Combining proteomic and clinical information, which are available before surgery, optimizes the prediction of which women have breast cancer.

Entities:  

Year:  2009        PMID: 20477526      PMCID: PMC3377166          DOI: 10.2217/bmm.09.46

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  20 in total

1.  Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human alpha S1 casein (alpha S1-casomorphin, and alpha S1-casomorphin amide).

Authors:  M Kampa; S Loukas; A Hatzoglou; P Martin; P M Martin; E Castanas
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

2.  Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry.

Authors:  Jianbo He; Jeffrey Gornbein; Dejun Shen; Ming Lu; Leonor E Rovai; Hungyi Shau; John Katz; Julian P Whitelegge; Kym F Faull; Helena R Chang
Journal:  Int J Oncol       Date:  2007-01       Impact factor: 5.650

3.  Cost-benefit analysis of biopsy methods for suspicious mammographic lesions; discussion 994-5.

Authors:  B N Fahy; R J Bold; P D Schneider; V Khatri; J E Goodnight
Journal:  Arch Surg       Date:  2001-09

4.  Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women.

Authors:  T Agurs-Collins; L L Adams-Campbell; K S Kim; K J Cullen
Journal:  Cancer Detect Prev       Date:  2000

5.  Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk.

Authors:  E R Sauter; E Ross; M Daly; A Klein-Szanto; P F Engstrom; A Sorling; J Malick; H Ehya
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.

Authors:  Constance D Lehman; Constantine Gatsonis; Christiane K Kuhl; R Edward Hendrick; Etta D Pisano; Lucy Hanna; Sue Peacock; Stanley F Smazal; Daniel D Maki; Thomas B Julian; Elizabeth R DePeri; David A Bluemke; Mitchell D Schnall
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

7.  A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.

Authors:  Yutaka Yasui; Margaret Pepe; Mary Lou Thompson; Bao-Ling Adam; George L Wright; Yinsheng Qu; John D Potter; Marcy Winget; Mark Thornquist; Ziding Feng
Journal:  Biostatistics       Date:  2003-07       Impact factor: 5.899

8.  Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer.

Authors:  Edward R Sauter; W Zhu; X-J Fan; R P Wassell; I Chervoneva; G C Du Bois
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

9.  A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer.

Authors:  J L Noble; R S Dua; G R Coulton; C M Isacke; G P H Gui
Journal:  Eur J Cancer       Date:  2007-09-27       Impact factor: 9.162

10.  Understanding the characteristics of mass spectrometry data through the use of simulation.

Authors:  Kevin R Coombes; John M Koomen; Keith A Baggerly; Jeffrey S Morris; Ryuji Kobayashi
Journal:  Cancer Inform       Date:  2005
View more
  6 in total

1.  Discrimination analysis of mass spectrometry proteomics for cervical cancer detection.

Authors:  Chibo Liu; Chunqin Pan; Jianmin Shen; Haibao Wang; Liang Yong; Richu Zhang
Journal:  Med Oncol       Date:  2010-11-16       Impact factor: 3.064

Review 2.  Proteomics and its applications in breast cancer.

Authors:  Anca-Narcisa Neagu; Danielle Whitham; Emma Buonanno; Avalon Jenkins; Teodora Alexa-Stratulat; Bogdan Ionel Tamba; Costel C Darie
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

3.  Protein biomarkers for the early detection of breast cancer.

Authors:  David E Misek; Evelyn H Kim
Journal:  Int J Proteomics       Date:  2011-08-11

4.  Diagnosis of gallbladder cancer using matrix-assisted laser desorption/ionization time-of-flight profiling.

Authors:  Yonghua Mou; Renwei Xing; Chibo Liu
Journal:  Am J Med Sci       Date:  2012-02       Impact factor: 2.378

Review 5.  Nipple Aspirate Fluid at a Glance.

Authors:  Susana I S Patuleia; Karijn P M Suijkerbuijk; Elsken van der Wall; Paul J van Diest; Cathy B Moelans
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

6.  [Preliminary study of MALDI-TOF mass spectrometry-based screening of patients with the NSCLC serum-specific peptides].

Authors:  Juan An; Chuanhao Tang; Na Wang; Yi Liu; Wanfeng Guo; Xiaoyan Li; Zihe Wang; Kun He; Xiaoqing Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.